Robert Ang, MBBS, MBA, is President and CEO at Vor Bio since 2019. Prior to Vor Bio, Robert gained operational experience focused on strategy and business development through roles at Neon Therapeutics (now BioNTech), Bavarian Nordic, and Cadence Pharmaceuticals (now Mallinckrodt). Robert also has biotech venture capital experience at Frazier Healthcare Ventures, where he invested in companies such as Incline Therapeutics (now Novartis) and Alnara Pharmaceuticals (now Eli Lilly), and strategy consulting experience at the Boston Consulting Group. He also has general surgery training and his clinical practice centered around soft tissue surgery with an emphasis on solid organ transplants. He received his medical degree at the University of Western Australia and has an MBA with Honors from Columbia Business School. Robert also serves as an independent director at the early-stage cancer immunotherapy company Enara Bio, a member of the Board of Directors and the Executive Committee of the Alliance for Regenerative Medicine, and a member of the Healthcare and Pharmaceutical Management Advisory Board of Columbia Business School.
Learn more about Robert’s views on the industry, the workplace, and other business topics in his CEO Perspectives blog.